Ceftriaxone Sodium | CAS#74578-69-1 (Na+) | Broad-Spectrum Cephalosporin Antibiotic

Ceftriaxone Sodium
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 317454

CAS#: 74578-69-1 (Na+)

Description: Ceftriaxone sodium is an antibiotic, a third-generation cephalosporin. Like other third-generation cephalosporins, it has broad-spectrum activity against Gram-positive bacteria and expanded Gram-negative coverage compared to second-generation agents. This includes pneumonia, ear infections, skin infections, urinary tract infections, gonorrhea, pelvic inflammatory disease, septisis, bone and joint infections, intra-abdominal infections, and meningitis. It is also used preoperatively to reduce the risk of postoperative infections. It is administered by intravenous or intramuscular injection.

Chemical Structure

Ceftriaxone Sodium

CAS# 74578-69-1 (Na+)

Instruction

Theoretical Analysis

MedKoo Cat#: 317454
Name: Ceftriaxone Sodium
CAS#: 74578-69-1 (Na+)
Chemical Formula: C18H17N8NaO7S3
Exact Mass: 0.00
Molecular Weight: 576.560
Elemental Analysis: C, 37.50; H, 2.97; N, 19.43; Na, 3.99; O, 19.42; S, 16.68

Price and Availability

Size	Price	Availability
1g	USD 250	2 Weeks
2g	USD 350	2 Weeks
5g	USD 650	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 73384-59-5 (free base) 74578-69-1 (Na+)

Synonym: Ceftriaxone Sodium; Ceftriaxone sodium hydrate; Ceftriaxonesodium; (E)-Ceftriaxone Sodium; Rocephine; Roche Brand of Ceftriaxone Sodium; Sodium, Ceftriaxone; Syntex Brand of Ceftriaxone Sodium; Tacex; Terbac;

IUPAC/Chemical Name: [(2S)-1-(4-Amino-2-oxopyrimidin-1-yl)-3-hydroxypropan-2-yl]oxymethylphosphonic acid

InChi Key: VWFCHDSQECPREK-LURJTMIESA-N

InChi Code: InChI=1S/C8H14N3O6P/c9-7-1-2-11(8(13)10-7)3-6(4-12)17-5-18(14,15)16/h1-2,6,12H,3-5H2,(H2,9,10,13)(H2,14,15,16)/t6-/m0/s1

SMILES Code: CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N/OC)/C4=CSC(=N4)N)SC2)C(=O)[O-].[Na+]

Appearance: White to light yellow solid powder.

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 576.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Xue J, Jia YH, Li J, Yin LH, Hu CQ. [Subtype classification of ceftriaxone
sodium and its influence on the quality of product]. Yao Xue Xue Bao. 2014
Jul;49(7):1034-8. Chinese. PubMed PMID: 25233636.

2: Pan J, Ye Z, Cai X, Wang L, Cao Z. Biophysical study on the interaction of
ceftriaxone sodium with bovine serum albumin using spectroscopic methods. J
Biochem Mol Toxicol. 2012 Dec;26(12):487-92. doi: 10.1002/jbt.21446. Epub 2012
Nov 21. PubMed PMID: 23169700.

3: Tange M, Hattori Y, Otsuka M, Yoshida M, Haginaka J, Uchida T. Comparison of
the dissolution rate of ceftriaxone sodium preparations for injection. Chem Pharm
Bull (Tokyo). 2013;61(11):1121-9. Epub 2013 Aug 16. PubMed PMID: 23955165.

4: Sun H, Wang H, Ge X. Simultaneous determination of the combined drugs of
ceftriaxone sodium, metronidazole, and levofloxacin in human urine by
high-performance liquid chromatography. J Clin Lab Anal. 2012 Nov;26(6):486-92.
doi: 10.1002/jcla.21551. PubMed PMID: 23143633.

5: Yao Y, Zhou R, Wang Y. Fatal adverse effects of injected ceftriaxone sodium in
China. Pharmacoepidemiol Drug Saf. 2012 Nov;21(11):1197-201. doi:
10.1002/pds.3232. Epub 2012 Jul 4. Review. PubMed PMID: 22761158.

6: Aléssio PV, Salgado HR. Development and validation of a successful
microbiological agar assay for determination of ceftriaxone sodium in powder for
injectable solution. Pharmaceutics. 2012 Jun 29;4(3):334-42. doi:
10.3390/pharmaceutics4030334. PubMed PMID: 24300294; PubMed Central PMCID:
PMC3834915.

7: Zaki NM, Hafez MM. Enhanced antibacterial effect of ceftriaxone sodium-loaded
chitosan nanoparticles against intracellular Salmonella typhimurium. AAPS
PharmSciTech. 2012 Jun;13(2):411-21. doi: 10.1208/s12249-012-9758-7. Epub 2012
Feb 23. PubMed PMID: 22359159; PubMed Central PMCID: PMC3364366.

8: Tange M, Yoshida M, Nakai Y, Uchida T. Comparison between original and generic
versions of ceftriaxone sodium preparation for injection: compatibility with
calcium-containing product. Chem Pharm Bull (Tokyo). 2012;60(4):429-34. PubMed
PMID: 22466725.

9: Akl MA, Ahmed MA, Ramadan A. Validation of an HPLC-UV method for the
determination of ceftriaxone sodium residues on stainless steel surface of
pharmaceutical manufacturing equipments. J Pharm Biomed Anal. 2011 May
15;55(2):247-52. doi: 10.1016/j.jpba.2011.01.020. Epub 2011 Jan 25. PubMed PMID:
21330092.

10: Zhang XH, Cao DM, Zhao SY, Gong P, Hei DQ, Zhang HQ. Gamma radiolysis of
ceftriaxone sodium for water treatment: assessments of the activity. Water Sci
Technol. 2011;63(12):2767-74. PubMed PMID: 22049697.

11: Sato Y, Morita H, Wakasugi H, Iijima S, Kawashima E, Wakayama Y, Yoshimura A.
Reversible choreoathetosis after the administration of ceftriaxone sodium in
patients with end-stage renal disease. Am J Med Sci. 2010 Nov;340(5):382-4. doi:
10.1097/MAJ.0b013e3181ec063b. PubMed PMID: 20724905.

12: Towfigh S, Pasternak J, Poirier A, Leister H, Babinchak T. A multicentre,
open-label, randomized comparative study of tigecycline versus ceftriaxone sodium
plus metronidazole for the treatment of hospitalized subjects with complicated
intra-abdominal infections. Clin Microbiol Infect. 2010 Aug;16(8):1274-81. doi:
10.1111/j.1469-0691.2010.03122.x. PubMed PMID: 20670293.

13: Nakai Y, Tokuyama E, Yoshida M, Uchida T. Prediction of incompatibility of
ceftriaxone sodium with calcium ions using the ionic product. Yakugaku Zasshi.
2010 Jan;130(1):95-102. PubMed PMID: 20046072.

14: Nakai Y, Tokuyama E, Yoshida M, Uchida T. Incompatibility of ceftriaxone
sodium with calcium-containing products. Yakugaku Zasshi. 2009
Nov;129(11):1385-92. PubMed PMID: 19881211.

15: Attama AA, Okafor CE, Builders PF, Okorie O. Formulation and in vitro
evaluation of a PEGylated microscopic lipospheres delivery system for ceftriaxone
sodium. Drug Deliv. 2009 Nov;16(8):448-57. doi: 10.3109/10717540903334959. PubMed
PMID: 19839789.

16: Zhao X, Jin SH, Hu CQ. The effect of rubber closures on the haze state of
ceftriaxone sodium for injection. Drug Dev Ind Pharm. 2007 Jan;33(1):35-44.
PubMed PMID: 17192249.

17: Stevenson AM. Ceftriaxone sodium. MCN Am J Matern Child Nurs. 1998
Sep-Oct;23(5):272. PubMed PMID: 9747091.

18: Bailey LC, Orosz ST Jr. Stability of ceftriaxone sodium and metronidazole
hydrochloride. Am J Health Syst Pharm. 1997 Feb 15;54(4):424-7. PubMed PMID:
9043566.

19: Plumridge RJ, Rieck AM, Annus TP, Langton SR. Stability of ceftriaxone sodium
in polypropylene syringes at -20, 4, and 20 degrees C. Am J Health Syst Pharm.
1996 Oct 1;53(19):2320-3. PubMed PMID: 8893073.

20: Rivers TE, Webster AA. Stability of ceftizoxime sodium, ceftriaxone sodium,
and ceftazidime with metronidazole in ready-to-use metronidazole bags. Am J
Health Syst Pharm. 1995 Nov 15;52(22):2568-70. PubMed PMID: 8590243.

Your view history

Ceftriaxone Sodium featured